Literature DB >> 35665371

Wilms' Tumor 1 (WT1): The Vaccine for Cancer.

Kyaw Zaw Hein1, Shuyang Yao2,3, Siqing Fu2.   

Abstract

Vaccines have been used to fight and protect against infectious diseases for centuries. With the emergence of immunotherapy in cancer treatment, researchers began investigating vaccines that could be used against cancer, especially against tumors that are resistant to conservative chemotherapy, surgery, and radiotherapy. The Wilms' tumor 1 (WT1) protein is immunogenic, has been detected in almost all types of malignancies, and has played a significant role in prognosis and disease monitoring. In this article, we review recent developments in the treatment of various types of cancers with the WT1 cancer vaccine; we also discuss theoretic considerations of various therapeutic approaches, which were based on preclinical and clinical data. © Innovative Healthcare Institute.

Entities:  

Keywords:  WT1 gene; cancer medicine; cancer vaccine; clinical trials; immunotherapy; leukemia; peptide-based vaccine; preclinical trails; solid cancer; toxicity

Year:  2020        PMID: 35665371      PMCID: PMC9165440          DOI: 10.36401/JIPO-20-12

Source DB:  PubMed          Journal:  J Immunother Precis Oncol        ISSN: 2590-017X


  64 in total

1.  Altered expression of the WT1 wilms tumor suppressor gene in human breast cancer.

Authors:  G B Silberstein; K Van Horn; P Strickland; C T Roberts; C W Daniel
Journal:  Proc Natl Acad Sci U S A       Date:  1997-07-22       Impact factor: 11.205

Review 2.  Opportunities and challenges in the immunological therapy of pediatric malignancy: a concise snapshot.

Authors:  Francesco Ceppi; Maja Beck-Popovic; Jean-Pierre Bourquin; Raffaele Renella
Journal:  Eur J Pediatr       Date:  2017-08-12       Impact factor: 3.183

3.  Wilms' tumor 1 susceptibility (WT1) gene products are selectively expressed in malignant mesothelioma.

Authors:  K M Amin; L A Litzky; W R Smythe; A M Mooney; J M Morris; D J Mews; H I Pass; C Kari; U Rodeck; F J Rauscher
Journal:  Am J Pathol       Date:  1995-02       Impact factor: 4.307

4.  Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation.

Authors:  R Childs; A Chernoff; N Contentin; E Bahceci; D Schrump; S Leitman; E J Read; J Tisdale; C Dunbar; W M Linehan; N S Young; A J Barrett
Journal:  N Engl J Med       Date:  2000-09-14       Impact factor: 91.245

5.  Cytotoxic T-lymphocyte responses elicited to Wilms' tumor gene WT1 product by DNA vaccination.

Authors:  A Tsuboi; Y Oka; H Ogawa; O A Elisseeva; H Li; K Kawasaki; K Aozasa; T Kishimoto; K Udaka; H Sugiyama
Journal:  J Clin Immunol       Date:  2000-05       Impact factor: 8.317

6.  Induction of complete and molecular remissions in acute myeloid leukemia by Wilms' tumor 1 antigen-targeted dendritic cell vaccination.

Authors:  Viggo F Van Tendeloo; Ann Van de Velde; Ann Van Driessche; Nathalie Cools; Sébastien Anguille; Kristin Ladell; Emma Gostick; Katrien Vermeulen; Katrien Pieters; Griet Nijs; Barbara Stein; Evelien L Smits; Wilfried A Schroyens; Alain P Gadisseur; Inge Vrelust; Philippe G Jorens; Herman Goossens; I Jolanda de Vries; David A Price; Yusuke Oji; Yoshihiro Oka; Haruo Sugiyama; Zwi N Berneman
Journal:  Proc Natl Acad Sci U S A       Date:  2010-07-14       Impact factor: 11.205

Review 7.  Therapeutic cancer vaccines.

Authors:  Cornelis J M Melief; Thorbald van Hall; Ramon Arens; Ferry Ossendorp; Sjoerd H van der Burg
Journal:  J Clin Invest       Date:  2015-07-27       Impact factor: 14.808

Review 8.  WT1 peptide vaccine for the treatment of cancer.

Authors:  Yoshihiro Oka; Akihiro Tsuboi; Yusuke Oji; Ichiro Kawase; Haruo Sugiyama
Journal:  Curr Opin Immunol       Date:  2008-05-24       Impact factor: 7.486

9.  Potential of dendritic-cell immunotherapy for relapse after allogeneic hematopoietic stem cell transplantation, shown by WT1 peptide- and keyhole-limpet-hemocyanin-pulsed, donor-derived dendritic-cell vaccine for acute myeloid leukemia.

Authors:  Toshio Kitawaki; Norimitsu Kadowaki; Tadakazu Kondo; Takayuki Ishikawa; Tatsuo Ichinohe; Satoshi Teramukai; Masanori Fukushima; Yasunari Kasai; Taira Maekawa; Takashi Uchiyama
Journal:  Am J Hematol       Date:  2008-04       Impact factor: 10.047

10.  Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines.

Authors:  L Zitvogel; J I Mayordomo; T Tjandrawan; A B DeLeo; M R Clarke; M T Lotze; W J Storkus
Journal:  J Exp Med       Date:  1996-01-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.